Source comparison
Mechanism of Action: GHRH Receptor vs Ghrelin Receptor
The most important distinction in this three-way comparison is the receptor pathway. Tesamorelin and sermorelin share one pathway. Ipamorelin uses a completely different one. Tesamorelin and sermorelin are both GHRH receptor agonists. They bind the GHRH recept
This comparison does not assign a generated winner or score.
- The most important distinction in this three-way comparison is the receptor pathway. Tesamorelin and sermorelin share one pathway. Ipamorelin uses a completely different one.
- Tesamorelin and sermorelin are both GHRH receptor agonists. They bind the GHRH receptor on pituitary somatotroph cells, triggering GH synthesis and release. Because they target the same receptor, stacking them together is pharmacologically redundant: the receptor can only respond so many times per hour regardless of how many agonists are competing for it.
- Ipamorelin targets the ghrelin receptor (GHS-R1a), which triggers GH release through a separate signaling cascade. When you pair a GHRH analog with ipamorelin, you activate two complementary pathways simultaneously. The GHRH analog stimulates GH production and synthesis. Ipamorelin prompts GH secretion. The result is a GH pulse larger than either compound achieves alone.
- Tesamorelin + Ipamorelin
- Yes
- GHRH + GHRP synergy (different receptors)
- Sermorelin + Ipamorelin
- Tesamorelin + Sermorelin
- No
- Both GHRH agonists (same receptor, redundant)
- Tesamorelin + CJC-1295
- All three together
- Two GHRH analogs in the mix is redundant
- Sermorelin + CJC-1295 + Ipamorelin
- Two GHRH analogs is still redundant
- For stacking guidance, see our peptide stacking guide.